Monthly Archives: February 2008

Suboptimal response in CML linked to Gleevec uptake in cells

Australian researchers have confirmed the protein involved in Gleevec’s transport into chronic myelogenousleukemia (CML) cells and have shown that it is the activity of this protein which is a key determinant of response in CML patients.

By |2019-09-16T12:10:54-04:00February 4th, 2008|Gleevec|

Molecular Clues Help Refine Kinase Inhibitor Strategy for GI

Robert G. Maki, M.D., Ph.D. talks about how molecular clues help refine Kinase Inhibitor strategy for GI. In the post-imatinib (Gleevec) era, treatment of gastrointestinal stromal tumors has shifted from serial surgeries to refinement of kinase [...]

By |2012-10-25T13:15:36-04:00February 1st, 2008|Video|

Serum Imatinib (Gleevec) Levels Predict GIST Response

Here is a video on Serum Imatinib (Gleevec) Levels Predict GIST Response. George D. Demetri, M.D., discusses how Gleevec levels  predict GIST response. Higher circulating levels of imatinib (Gleevec) correlated with better clinical responses in patients with [...]

By |2014-09-03T13:23:03-04:00February 1st, 2008|Video|
Go to Top